A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

NCT02755649 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

325

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab
DRUG: Matching Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]